[Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Twenty-five patients, 12 men and 13 women, 42 to 79 years (mean 62) were studied to determine possible interest of a controlled release preparation of L. dopa combined with benserazide. All patients were experiencing fluctuations in efficacy over the last 8 +/- 4 years. Their Parkinson disease was of long duration, (16 +/- 5 years), severe (Hoehn and Yahr's stages III to V) and treated with L. dopa for 12 +/- 4 years. Results were evaluated in the short, medium and long term. During the initial period the new treatment was substituted for previous therapy on a dose for dose basis. Long term (300 days) results showed that "end of dose" fluctuations had been improved in 40 p. 100 of cases without concomitant reduction in therapeutic effects, duration of "ON" periods progressing by 60%. The frequency of drug intake was unaltered but daily dosage could be increased by 30% without increasing severity of abnormal movements to a similar degree. The administration of this new presentation can be recommended, especially when frequent fluctuations compromise long term therapeutic effects.
Rondot
P
P
Service de Neurologie, CHSA, Centre Raymond Garcin, Paris.
Ziegler
M
M
Aymard
N
N
Holzer
J
J
D000328:Adult; D000368:Aged; D001545:Benserazide / Q000627:therapeutic use*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004338:Drug Combinations / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006834:Hydrazines; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide; D002262:Carboxy-Lyases
Levodopa-bensérazide a libération contrôlée et fluctuations d'efficacité au cours du traitement de la maladie de Parkinson.